Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 19/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 17/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 8/20 | 0.59 |
| ▸ | L3MBTL4 | Q8NA19 | 3/20 | 0.57 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085344 | 0.84 | L3MBTL3 (0.72) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1085239 | 0.81 | L3MBTL3 (0.67) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL1156011 | 0.81 | LMNA (0.56) | L3MBTL1 | |
| SCHEMBL1085624 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL2366162 | 0.78 | MGLL (0.64) | — | |
| SCHEMBL1083750 | 0.77 | CACNA1B (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL2366054 | 0.76 | POLB (0.48) | — | |
| SCHEMBL23682705 | 0.74 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL29613449 | 0.74 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 | |
| SCHEMBL27223857 | 0.74 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1L3MBTL4TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2205583-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | L3MBTL3 1629/4885L3MBTL1 2710/4885MBTD1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.